Metabolic syndrome up with ADT in prostate cancer

Metabolic syndrome up with ADT in prostate cancer

(HealthDay)—For patients with prostate cancer treated with androgen deprivation therapy there are increases in components of metabolic syndrome and in the prevalence of full metabolic syndrome, according to a study published in the June issue of The Journal of Urology.

Juan Morote, M.D., from Hospital Vall d'Hebron and Universitat Autónoma de Barcelona in Spain, and colleagues conducted an observational prospective study involving 539 patients scheduled to receive three-month depot luteinizing hormone-releasing hormone analogs for longer than 12 months. The authors examined the prevalence of full metabolic syndrome, assessed according to different definitions, and its components.

The researchers found that at six and 12 months after initiation there were significant increases in waist circumference, body mass index, fasting glucose, triglycerides, total cholesterol, and high- and . There were no significant changes in blood pressure of 130/85 mm Hg or greater. There was a nonsignificant increase in the prevalence of full metabolic syndrome, based on National Cholesterol Education Program Adult Treatment Panel III criteria (baseline, 22.9 percent versus 25.5 percent at six months and 26.8 percent at 12 months). At 12 months there were significant increases in prevalence with two of the definitions (World Health Organization, 4.1 percent and American Heart Association/National Heart, Lung, and Blood Institute, 8.1 percent).

"Counseling patients on the prevention, early detection, and treatment of specific metabolic alterations is recommended," the authors write.

The study was funded by Ipsen Pharma.


Explore further

People with metabolic syndrome face higher cardiovascular death risk

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: Journal of Urology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Metabolic syndrome up with ADT in prostate cancer (2015, June 4) retrieved 18 July 2019 from https://medicalxpress.com/news/2015-06-metabolic-syndrome-adt-prostate-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more